Cargando…

False Positive Findings of [(18)F]PSMA-1007 PET/CT in Patients After Radical Prostatectomy with Undetectable Serum PSA Levels

BACKGROUND: PET-CT using prostate-specific membrane antigen (PSMA)-targeting radiopharmaceuticals labeled with (68)Ga or (18)F has emerged as the most sensitive staging tool in prostate cancer (PC). Nonetheless, the occurrence of false positive (FP) findings presents a major concern of this approach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Orevi, Marina, Ben-Haim, Simona, Abourbeh, Galith, Chicheportiche, Alexandre, Mishani, Eyal, Yutkin, Vladimir, Gofrit, Ofer N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263625/ https://www.ncbi.nlm.nih.gov/pubmed/35813044 http://dx.doi.org/10.3389/fsurg.2022.943760

Ejemplares similares

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Real‐world Israeli single institution experience with PET‐PSMA for staging of patients with clinically staged localized prostate carcinoma
por: Zarbiv, Yonaton, et al.
Publicado: (2021)

Organic Cation Transporter-Mediated Accumulation of Quinolinium Salts in the LV Myocardium of Rodents
por: Grievink, Hilbert, et al.
Publicado: (2022)

Gating, enhanced gating, and beyond: information utilization strategies for motion management, applied to preclinical PET
por: Kesner, Adam Leon, et al.
Publicado: (2013)

Development and preclinical evaluation of novel fluorinated ammonium salts for PET myocardial perfusion imaging
por: Shamni, Ofer, et al.
Publicado: (2021)

Evaluation of (18)F-PSMA-1007 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy
por: Zhou, Xing, et al.
Publicado: (2021)

Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival
por: Doherty, A P, et al.
Publicado: (2000)

Heterophilic Antibodies Resulting in False Positive Elevation of PSA After Radical Prostatectomy
por: Asha, Wafa, et al.
Publicado: (2023)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA PET/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy
por: von Eyben, Finn Edler, et al.
Publicado: (2021)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

(68)Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
por: Yuminaga, Yuigi, et al.
Publicado: (2021)

Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies
por: Orevi, Marina, et al.
Publicado: (2022)

The prognostic value of (18)F-PSMA-1007 PET/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy
por: Zheng, Anqi, et al.
Publicado: (2023)

Changes of Radiation Treatment Concept Based on (68)Ga-PSMA-11-PET/CT in Early PSA-Recurrences After Radical Prostatectomy
por: Bottke, Dirk, et al.
Publicado: (2021)

[(18)F]-FDHT PET/CT as a tool for imaging androgen receptor expression in high-grade glioma
por: Orevi, Marina, et al.
Publicado: (2021)

(18) F-FDG PET/CT Imaging of Boari Flap Mimicking Urothelial Cancer Recurrence
por: Fishberg, Sharon E., et al.
Publicado: (2022)

Transurethral Prostatectomy Before or After External Beam Radiotherapy: Complications and Reoperation Rates
por: Molineros, Gabriel, et al.
Publicado: (2021)

PSMA-Positive Low Malignant Gastrointestinal Stromal Tumor in the Stomach on F-18-PSMA-1007 PET/CT
por: Iversen, Peter, et al.
Publicado: (2022)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Comparison of NEMA characterizations for Discovery MI and Discovery MI-DR TOF PET/CT systems at different sites and with other commercial PET/CT systems
por: Chicheportiche, Alexandre, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

Case Report: (18)F-PSMA-1007 PET/CT Avid Solitary Penile Metastasis of Castration-Resistant Prostate Cancer With a PSA of 0.072 ng/ml
por: Li, Yongliang, et al.
Publicado: (2022)

The natural history of a delayed detectable PSA after radical prostatectomy
por: Szymaniak, Julie A., et al.
Publicado: (2023)

(18)F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report
por: Wang, Long, et al.
Publicado: (2021)

Non-prostate uptake on (18)F-PSMA-1007 PET/CT: a case of myeloma
por: Veerasuri, Sowmya, et al.
Publicado: (2020)

Dose-reduced [(18)F]PSMA-1007 PET is feasible for functional imaging of the renal cortex
por: Valind, Kristian, et al.
Publicado: (2021)

(18)F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis
por: Ferrari, Matteo, et al.
Publicado: (2021)

Diagnostic accuracy of [(18)F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
por: Mingels, Clemens, et al.
Publicado: (2022)

Biokinetics and dosimetry of (18)F‐PSMA‐1007 in patients with prostate cancer
por: Hvittfeldt, Erland, et al.
Publicado: (2022)

Skeletal (18)F-PSMA-1007 uptake in prostate cancer patients
por: Janssen, Jorinde, et al.
Publicado: (2023)

Identification of the Optimal Cut-Off Value of PSA for Assessing Severity of Disease in [(68)Ga]Ga-PSMA-11 PET/CT Study in Prostate Cancer Patients after Radical Prostatectomy
por: Cegla, Paulina, et al.
Publicado: (2022)

Protocol for SNOTOB study: radical prostatectomy without prostate biopsy following (18)F-PSMA-1007 PET/CT based on a diagnostic model: a single-centre, single-arm, open-label study
por: Wang, Changming, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

PSA mass as a marker of prostate cancer progression after radical prostatectomy
por: Bryniarski, Piotr, et al.
Publicado: (2011)

Preclinical comparative study of [(18)F]AlF-PSMA-11 and [(18)F]PSMA-1007 in varying PSMA expressing tumors
por: Piron, Sarah, et al.
Publicado: (2022)

Metastatic-directed therapy using PSMA-PET/CT at PSA relapse
por: Lilleby, Oscar, et al.
Publicado: (2019)

Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature
por: Loudas, Nicholas B., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c811t8trqtgb7v6irbafogq2sr